ExxonMobil and Porsche Expand Motorsports Technology Partnership Into Formula E
6.9.2019 16:00:00 EEST | Business Wire | Press release
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. The new partnership represents ExxonMobil’s first entry into electric motorsports.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190906005023/en/
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. (Photo: Business Wire)
Starting from the first race in Saudi Arabia at the end of this year, ExxonMobil will provide Mobil-branded high-performance electric powertrain fluids to Porsche, developed specifically to meet the specialized demands of electric vehicles.
“Our entry into Formula E with Porsche not only represents an expansion to our successful business relationship, but an expansion of a winning partnership in racing,” said Russ Green, vice president, finished lubricants at ExxonMobil. “As Porsche begins to compete and demonstrate the capabilities of its electric vehicle technology, ExxonMobil is engineering a full suite of Mobil-branded lubricants to help the new Porsche Formula E team build on its legacy of racing success around the world. Motorsport provides the ultimate proving ground to continue to develop high-performance lubricants and fluids.”
Vehicles competing in electric motorsports benefit from high-performance lubricant technology that provides specialized advantages needed for the car’s battery pack including electrical conductivity, cooling capabilities and material compatibility.
“As a key technical partner of more than 20 years, no other lubricant supplier understands the Porsche performance philosophy like ExxonMobil,” said Fritz Enzinger, vice president, Porsche Motorsport. “ExxonMobil has not only been a valuable partner for our commercial business, but an important teammate in our pursuit of wins and championships from Sebring to Le Mans. They were a natural addition to our Formula E team as we enter an exciting new era of racing for Porsche.”
The new technical partnership joins ExxonMobil’s existing roster of global motorsports activities with Porsche including the World Endurance Championships, IMSA WeatherTech SportsCar Championship, Porsche Mobil 1 Supercup, Porsche Carrera Cup and numerous customer racing activities around the world.
About ExxonMobil
ExxonMobil, the largest publicly traded international oil and gas company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products, and its chemical company is one of the largest in the world.
About ExxonMobil in Motorsports
Racing provides ExxonMobil and its lubricants and fuels brands the ultimate testing ground to improve the technology in our range of oil, lubricants and fuels. Each race season, our advanced products go to work to help improve vehicle performance and efficiency. ExxonMobil products serve as the lubricant of choice for many of the world’s top race teams competing in highly demanding motorsports series. The knowledge we gain through these partnerships helps our scientists and engineers push the boundaries in developing cutting-edge technologies.
ExxonMobil remains proud partners with Aston Martin Red Bull Racing, Stewart-Haas Racing in NASCAR’s Sprint Cup Series; Porsche, Bentley and TOYOTA GAZOO Racing in the FIA World Endurance Championship; Corvette Racing, Porsche North America, Lexus and Acura/Caterpillar in the IMSA WeatherTech SportsCar Championship; and numerous teams competing in series around the world.
For more information about ExxonMobil and its brands, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190906005023/en/
Contact information
Media Relations
832-625-4000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom